CD4 and neoplasm: Although tumor tissues treated with ribociclib or trametinib as monotherapies tended to show more CD3- and CD4-positive cells, combination therapy did not change CD3/CD4/CD8 expressions compared with those of tumors that received vehicle (S5B-S5D Fig).